|
EPS8 |
epidermal growth factor receptor pathway substrate 8 |
|
|
|
|
ERBB2 |
erb-b2 receptor tyrosine kinase 2 |
- Signaling by ERBB2
- SHC1 events in ERBB2 signaling
- SHC1 events in ERBB2 signaling
- PLCG1 events in ERBB2 signaling
- PIP3 activates AKT signaling
- GRB7 events in ERBB2 signaling
- Downregulation of ERBB2:ERBB3 signaling
- GRB2 events in ERBB2 signaling
- GRB2 events in ERBB2 signaling
- PI3K events in ERBB2 signaling
- Constitutive Signaling by Aberrant PI3K in Cancer
- Sema4D induced cell migration and growth-cone collapse
- RAF/MAP kinase cascade
- ERBB2 Regulates Cell Motility
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- ERBB2 Activates PTK6 Signaling
- Downregulation of ERBB2 signaling
- TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
- Constitutive Signaling by Overexpressed ERBB2
- Drug-mediated inhibition of ERBB2 signaling
- Signaling by ERBB2 KD Mutants
- Resistance of ERBB2 KD mutants to trastuzumab
- Resistance of ERBB2 KD mutants to sapitinib
- Resistance of ERBB2 KD mutants to tesevatinib
- Resistance of ERBB2 KD mutants to neratinib
- Resistance of ERBB2 KD mutants to osimertinib
- Resistance of ERBB2 KD mutants to afatinib
- Resistance of ERBB2 KD mutants to AEE788
- Resistance of ERBB2 KD mutants to lapatinib
- Signaling by ERBB2 ECD mutants
- Signaling by ERBB2 TMD/JMD mutants
- Drug resistance in ERBB2 TMD/JMD mutants
|
- Trastuzumab
- Lapatinib
- IGN311
- Trastuzumab emtansine
- Varlitinib
- AV-412
- Pertuzumab
- Afatinib
- Tucatinib
- Tesevatinib
- Fostamatinib
- Brigatinib
- Margetuximab
- Zanubrutinib
|
- Choriocarcinoma
- Pancreatic cancer
- Gastric cancer
- Bladder cancer
- Endometrial Cancer
- Ovarian cancer
- Cholangiocarcinoma
- Breast cancer
- Cervical cancer
|
|
ERBB3 |
erb-b2 receptor tyrosine kinase 3 |
|
|
- Lethal congenital contractural syndrome (LCCS)
- Type I diabetes mellitus
|
|
ERBB4 |
erb-b2 receptor tyrosine kinase 4 |
|
- Afatinib
- Fostamatinib
- Brigatinib
- Zanubrutinib
|
|
|
EREG |
epiregulin |
- Signaling by ERBB2
- Signaling by ERBB4
- SHC1 events in ERBB2 signaling
- SHC1 events in ERBB2 signaling
- PI3K events in ERBB4 signaling
- SHC1 events in ERBB4 signaling
- Nuclear signaling by ERBB4
- PIP3 activates AKT signaling
- Signaling by EGFR
- GRB2 events in EGFR signaling
- GAB1 signalosome
- SHC1 events in EGFR signaling
- EGFR downregulation
- GRB2 events in ERBB2 signaling
- PI3K events in ERBB2 signaling
- EGFR interacts with phospholipase C-gamma
- Constitutive Signaling by Aberrant PI3K in Cancer
- Inhibition of Signaling by Overexpressed EGFR
- RAF/MAP kinase cascade
- ERBB2 Regulates Cell Motility
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- ERBB2 Activates PTK6 Signaling
- Cargo recognition for clathrin-mediated endocytosis
- Clathrin-mediated endocytosis
- Downregulation of ERBB2 signaling
- Extra-nuclear estrogen signaling
- Estrogen-dependent nuclear events downstream of ESR-membrane signaling
- Signaling by ERBB2 KD Mutants
- Signaling by ERBB2 TMD/JMD mutants
|
|
|
|
ERRFI1 |
ERBB receptor feedback inhibitor 1 |
|
|
|
|
ESR1 |
estrogen receptor 1 |
- Nuclear signaling by ERBB4
- PIP3 activates AKT signaling
- Constitutive Signaling by Aberrant PI3K in Cancer
- Nuclear Receptor transcription pathway
- SUMOylation of intracellular receptors
- Ovarian tumor domain proteases
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
- RUNX1 regulates estrogen receptor mediated transcription
- ESR-mediated signaling
- RUNX1 regulates transcription of genes involved in WNT signaling
- Regulation of RUNX2 expression and activity
- Regulation of RUNX2 expression and activity
- Extra-nuclear estrogen signaling
- Estrogen-dependent gene expression
|
- Diethylstilbestrol
- Chlorotrianisene
- Conjugated estrogens
- Desogestrel
- Levonorgestrel
- Progesterone
- Lindane
- Raloxifene
- Toremifene
- Medroxyprogesterone acetate
- Testosterone
- Mitotane
- Estrone
- Tamoxifen
- Hexachlorophene
- Estradiol
- Ethynodiol diacetate
- Dobutamine
- Clomifene
- Dienestrol
- Fulvestrant
- Norgestimate
- Ethinylestradiol
- Melatonin
- Trilostane
- Naloxone
- Fluoxymesterone
- Estramustine
- Mestranol
- Danazol
- Oxybenzone
- Allylestrenol
- Zinc
- Genistein
- Prasterone
- Benzophenone
- Equilin
- Compound 19
- Resveratrol
- Compound 18
- Phthalic Acid
- Pyrazole
- Stanolone
- Naringenin
- Compound 4-D
- 1-[4-(Octahydro-Pyrido[1,2-a]Pyrazin-2-Yl)-Phenyl]-2-Phenyl-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol
- Quercetin
- Afimoxifene
- 2-Phenyl-1-[4-(2-Piperidin-1-Yl-Ethoxy)-Phenyl]-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol
- Estriol
- Estrone sulfate
- Quinestrol
- Phenolphthalein
- Permethrin
- Ospemifene
- AP1081
- Custirsen
- NP-50301
- CHF 4227
- TAS-108
- Lasofoxifene
- Arzoxifene
- Elacestrant
- Bazedoxifene
- Methyltestosterone
- beta-Naphthoflavone
- 17-METHYL-17-ALPHA-DIHYDROEQUILENIN
- 4-(2-amino-1-methyl-1H-imidazo[4,5-b]pyridin-6-yl)phenol
- [5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-YL]ACETONITRILE
- 4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-8-METHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
- 4-[(1S,2S,5S,9R)-5-(HYDROXYMETHYL)-8,9-DIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
- 4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-6,8,9-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
- (2R,3R,4S)-3-(4-HYDROXYPHENYL)-4-METHYL-2-[4-(2-PYRROLIDIN-1-YLETHOXY)PHENYL]CHROMAN-6-OL
- (3AS,4R,9BR)-2,2-DIFLUORO-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL
- (9ALPHA,13BETA,17BETA)-2-[(1Z)-BUT-1-EN-1-YL]ESTRA-1,3,5(10)-TRIENE-3,17-DIOL
- (9BETA,11ALPHA,13ALPHA,14BETA,17ALPHA)-11-(METHOXYMETHYL)ESTRA-1(10),2,4-TRIENE-3,17-DIOL
- 3-CHLORO-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL
- 3-ETHYL-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL
- Hexestrol
- dimethyl (1R,4S)-5,6-bis(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hepta-2,5-diene-2,3-dicarboxylate
- Erteberel
- N-[(1R)-3-(4-HYDROXYPHENYL)-1-METHYLPROPYL]-2-(2-PHENYL-1H-INDOL-3-YL)ACETAMIDE
- (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-6-(METHOXYMETHYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL
- 4-[1-allyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol
- 4-(6-HYDROXY-1H-INDAZOL-3-YL)BENZENE-1,3-DIOL
- DIETHYL (1R,2S,3R,4S)-5,6-BIS(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT-5-ENE-2,3-DICARBOXYLATE
- 2-Amino-1-methyl-6-phenylimidazo(4,5-b)pyridine
- 4-[(1S,2R,5S)-4,4,8-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
- (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-9-OL
- 2-(4-hydroxyphenyl)benzo[b]thiophen-6-ol
- Tibolone
- Eugenol
- Synthetic Conjugated Estrogens, A
- Synthetic Conjugated Estrogens, B
- Polyestradiol phosphate
- Norethynodrel
- Octocrylene
- Homosalate
- Enzacamene
- Zeranol
- Ractopamine
- Gestrinone
- Propyl Gallate
- 2-Methoxy-6-{(E)-[(4-methylphenyl)imino]methyl}phenol
- Testosterone cypionate
- Testosterone enanthate
- Testosterone undecanoate
- Stanolone acetate
- Estradiol acetate
- Estradiol benzoate
- Estradiol cypionate
- Estradiol dienanthate
- Estradiol valerate
- Zinc acetate
- Zinc chloride
- Zinc sulfate, unspecified form
- Estriol tripropionate
- Fluoroestradiol F-18
|
|
|
EZR |
ezrin |
- Netrin-1 signaling
- Recycling pathway of L1
- Recycling pathway of L1
|
|
|
|
FAH |
fumarylacetoacetate hydrolase |
|
- Fumaric Acid
- Acetoacetic acid
- 4-[Hydroxy-[Methyl-Phosphinoyl]]-3-Oxo-Butanoic Acid
|
- Tyrosinemia; Tyrosinemia, type I; Tyrosinemia, type II; Tyrosinemia, type III; Hawkinsinuria
|
|
FANCC |
FA complementation group C |
- Fanconi Anemia Pathway
- TP53 Regulates Transcription of DNA Repair Genes
|
|
|
|
FAS |
Fas cell surface death receptor |
- Caspase activation via Death Receptors in the presence of ligand
- Regulation by c-FLIP
- RIPK1-mediated regulated necrosis
- CASP8 activity is inhibited
- TP53 Regulates Transcription of Death Receptors and Ligands
- Dimerization of procaspase-8
- FasL/ CD95L signaling
|
|
- Hodgkin lymphoma
- Esophageal cancer
- Chronic lymphocytic leukemia (CLL)
- Adult T-cell leukemia
|
|
FBXO25 |
F-box protein 25 |
|
|
|
|
FER |
FER tyrosine kinase |
|
|
|
|
FES |
FES proto-oncogene, tyrosine kinase |
- Signaling by SCF-KIT
- Sema3A PAK dependent Axon repulsion
- SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion
- CRMPs in Sema3A signaling
|
|
|
|
FGR |
FGR proto-oncogene, Src family tyrosine kinase |
- FCGR activation
- Platelet sensitization by LDL
- Neutrophil degranulation
- FCGR3A-mediated IL10 synthesis
- FCGR3A-mediated phagocytosis
|
- Dasatinib
- Fostamatinib
- Zanubrutinib
|
|
|
FKBP4 |
FKBP prolyl isomerase 4 |
- HSP90 chaperone cycle for steroid hormone receptors (SHR)
- Attenuation phase
- ESR-mediated signaling
- Estrogen-dependent gene expression
- Potential therapeutics for SARS
|
|
|
|
FKBP8 |
FKBP prolyl isomerase 8 |
- Ub-specific processing proteases
|
|
|
|
FN1 |
fibronectin 1 |
- Platelet degranulation
- Degradation of the extracellular matrix
- Degradation of the extracellular matrix
- Extracellular matrix organization
- Fibronectin matrix formation
- Cell surface interactions at the vascular wall
- Molecules associated with elastic fibres
- Integrin cell surface interactions
- Syndecan interactions
- Non-integrin membrane-ECM interactions
- ECM proteoglycans
- Integrin signaling
- GRB2:SOS provides linkage to MAPK signaling for Integrins
- p130Cas linkage to MAPK signaling for integrins
- Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
- MAP2K and MAPK activation
- Interleukin-4 and Interleukin-13 signaling
- Signaling by moderate kinase activity BRAF mutants
- Signaling by high-kinase activity BRAF mutants
- Signaling by BRAF and RAF fusions
- Paradoxical activation of RAF signaling by kinase inactive BRAF
- MET activates PTK2 signaling
- Post-translational protein phosphorylation
- Signaling downstream of RAS mutants
- Signaling by RAF1 mutants
|
- Zinc
- Lanoteplase
- Ocriplasmin
- Zinc acetate
- Zinc chloride
- Zinc sulfate, unspecified form
|
|
|
FRAT2 |
FRAT regulator of WNT signaling pathway 2 |
- Beta-catenin phosphorylation cascade
- Disassembly of the destruction complex and recruitment of AXIN to the membrane
|
|
|
|
FRK |
fyn related Src family tyrosine kinase |
- Neutrophil degranulation
- Regulation of PTEN stability and activity
|
- Dasatinib
- Regorafenib
- Fostamatinib
- Zanubrutinib
|
|